Severe Raynaud syndrome induced by adjuvant interferon alfa in metastatic melanoma
Husein Husein-ElAhmed,J.L. Callejas-Rubio,R. Ortega Del Olmo,R. Rios-Fernandez,N. Ortego-Centeno +4 more
5
TL;DR: A case of severe Raynaud syndrome and digital necrosis induced by interferon alfa in a patient with melanoma is presented.
read more
Abstract: Melanoma is the most lethal form of skin malignancy because of its aggressive behaviour. In advanced disease, interferon alfa can be used as adjuvant therapy. However, this therapy is not free of side effects. We present a case of severe Raynaud syndrome and digital necrosis induced by interferon alfa in a patient with melanoma. Pathogenic mechanisms are discussed.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Iatrogenic Raynaud phenomenon: a systematic review and a network meta-analysis of peripheral vasoconstriction induced by beta-blockers
Charles Khouri
- 03 Jul 2015
TL;DR: Important heterogeneity among beta-blockers is revealed, with a protective effect of intrinsic sympathomimetic activity as compared with β1-aderenoceptors higher affinity, and recommendations on the use of beta- blockers inpatients presenting RP and PV are challenged.
3
Rheumatologic/Orthopedic Emergencies
Huifang Lu,Maria E. Suarez-Almazor +1 more
- 01 Jan 2016
TL;DR: Patients with cancer frequently present with signs and symptoms of musculoskeletal and rheumatic diseases, and cancer patients with pre-existing rheumatologic diseases can experience flare-ups of those diseases that require urgent intervention.
Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.
Charles Khouri,Sophie Blaise,Sophie Blaise,Patrick H. Carpentier,Céline Villier,Jean-Luc Cracowski,Jean-Luc Cracowski,Matthieu Roustit,Matthieu Roustit +8 more
TL;DR: In this paper, a systematic review of English and French language articles was performed through Medline (1946-2015) and Embase (1974-2015), and the authors identified 12 classes of drugs responsible for Raynaud's phenomenon with a variety of underlying mechanisms such as increased sympathetic activation, endothelial dysfunction, neurotoxicity or decreased red blood cell deformability.
Vasculitis Con Necrosis Digital Asociada Con Interferón Beta
Evangelina Miretti,Laura Encinas,Marcela Colazo,María Hayes Salina,Verónica Saurit,Francisco Caeiro,Alejandro Alvarellos +6 more
TL;DR: A case report describes a patient developing digital necrosis associated with interferon beta administration, highlighting a rare side effect of this biologic therapy, which has been linked to skin lesions and severe Raynaud's syndrome in previous cases.
References
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
John M. Kirkwood,Myla Hunt Strawderman,Marc S. Ernstoff,Thomas J. Smith,Ernest C. Borden,Ronald H. Blum +5 more
TL;DR: IFN alpha-2b is the first agent to show a significant benefit in relapse-free and overall survival of high-risk melanoma patients in a randomized controlled trial.
2.1K
High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801
John M. Kirkwood,Joseph Ibrahim,Jeffrey A. Sosman,Vernon K. Sondak,Sanjiv S. Agarwala,Marc S. Ernstoff,Uma Rao +6 more
TL;DR: A significant treatment benefit of HDI versus GMK in terms of RFS and OS in melanoma patients at high risk of recurrence is demonstrated in this prospective, randomized, intergroup trial.
940
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
J. M. Kirkwood,M. H. Strawderman,Marc S. Ernstoff,T. J. Smith,E. C. Borden,R. H. Blum +5 more
TL;DR: IFN alpha-2b is the first agent to show a significant benefit in relapse-free and overall survival of high-risk melanoma patients in a randomized controlled trial.
336
Developing Indications for the Use of Sentinel Lymph Node Biopsy and Adjuvant High-Dose Interferon Alfa-2b in Melanoma
Robert W. Dubois,Susan M. Swetter,Michael B. Atkins,Kelly M. McMasters,Ronald J. Halbert,Stanley J. Miller,Ronald Shiell,John M. Kirkwood +7 more
TL;DR: A multidisciplinary panel of dermatologists, surgical oncologists, and medical oncologist to formally review available data on the sentinel lymph node (SLN) biopsy procedure and high-dose adjuvant interferon alfa-2b therapy for patients with melanoma and to rate the "appropriateness" of the procedure and therapy to guide clinical decision making in practice.
76